Clinical Trials on Sarcoglycanopathies

Total 6 results

Sarepta Therapeutics, Inc.

Active, not recruiting

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Limb-Girdle Muscular Dystrophy, Type 2E

United States
Atamyo Therapeutics

Not yet recruiting

Natural History Study in Patients With LGMDR5/2c

Gamma-sarcoglycanopathy

France, Tunisia
Sarepta Therapeutics, Inc.

Recruiting

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Limb-girdle Muscular Dystrophy

United States, Brazil, Belgium, Canada, Germany, Italy, Spain, Sweden, Turkey, United Kingdom
Sarepta Therapeutics, Inc.
Nationwide Children's Hospital

Completed

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

Limb-Girdle Muscular Dystrophy, Type 2D
Nationwide Children's Hospital
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)

Muscular Dystrophies

United States
Genethon

Completed

Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C

Limb Girdle Muscular Dystrophy Type 2C | Gamma-sarcoglycanopathy

France

3

Subscribe